Matinas BioPharma Holdings, Inc. (MTNB)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Unrealized gain on securities available-for-sale | - | 51 | 83 | |
| Other comprehensive gain, net of tax | - | 51 | 83 | |
| Other income, net | -63 | 106 | 120 | |
| Research and development | - | 2,239 | 3,371 | |
| General and administrative | 1,837 | 2,142 | 2,468 | |
| Total costs and expenses | 1,837 | 4,381 | 5,839 | |
| Loss from operations | -1,837 | -4,381 | -5,839 | |
| Gain on sale of assets, net | 110 | - | - | |
| Change in fair value of warrant liability | 3,455 | - | - | |
| Net loss | -5,245 | -4,275 | -5,719 | |
| Comprehensive loss | -5,245 | -4,224 | -5,636 | |
| Net loss per share - basic | -1.03 | -0.85 | -0.02 | |
| Net loss per share - diluted | -1.03 | -0.85 | -0.02 | |
| Weighted average common shares outstanding - basic | 5,086,985 | 5,037,829 | 249,350,963 | |
| Weighted average common shares outstanding - diluted | 5,086,985 | 5,037,829 | 249,350,963 | |